These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Change in the spectrum of RET mutations diagnosed between 1994 and 2006. Frank-Raue K; Rondot S; Schulze E; Raue F Clin Lab; 2007; 53(5-6):273-82. PubMed ID: 17605401 [TBL] [Abstract][Full Text] [Related]
4. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation. Frank-Raue K; Raue F Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387 [TBL] [Abstract][Full Text] [Related]
5. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Yip L; Cote GJ; Shapiro SE; Ayers GD; Herzog CE; Sellin RV; Sherman SI; Gagel RF; Lee JE; Evans DB Arch Surg; 2003 Apr; 138(4):409-16; discussion 416. PubMed ID: 12686527 [TBL] [Abstract][Full Text] [Related]
7. [Neural crest and multiple endocrinopathies]. Pasini A; Michiels FM; Chappuis-Flament S; Geneste O; Rossel M; Fournier L; Feunteun J; Lenoir G; Schuffenecker I; Billaud M C R Seances Soc Biol Fil; 1996; 190(5-6):557-67. PubMed ID: 9074721 [TBL] [Abstract][Full Text] [Related]
8. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan. Kameyama K; Okinaga H; Takami H Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413 [TBL] [Abstract][Full Text] [Related]
9. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal. Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668 [TBL] [Abstract][Full Text] [Related]
10. A large family with hereditary MTC: role of RET genetic analysis in differential diagnosis between MEN 2A and FMTC. Chiefari E; Chiarella R; Crocetti U; Tardio B; Arturi F; Russo D; Trischitta V; Filetti S; Zingrillo M Horm Metab Res; 2001 Jan; 33(1):52-6. PubMed ID: 11280716 [TBL] [Abstract][Full Text] [Related]
11. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma. Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251 [TBL] [Abstract][Full Text] [Related]
12. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Raue F; Frank-Raue K Hormones (Athens); 2009; 8(1):23-8. PubMed ID: 19269918 [TBL] [Abstract][Full Text] [Related]
13. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320 [TBL] [Abstract][Full Text] [Related]
14. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097 [TBL] [Abstract][Full Text] [Related]
15. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer? Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the role of RET polymorphisms/haplotypes as modifier loci for MEN 2, and analysis of the correlation with the type of RET mutation in a series of Spanish patients. Fernández RM; Navarro E; Antiñolo G; Ruiz-Ferrer M; Borrego S Int J Mol Med; 2006 Apr; 17(4):575-81. PubMed ID: 16525712 [TBL] [Abstract][Full Text] [Related]
17. Current approaches to medullary thyroid carcinoma, sporadic and familial. Fialkowski EA; Moley JF J Surg Oncol; 2006 Dec; 94(8):737-47. PubMed ID: 17131404 [TBL] [Abstract][Full Text] [Related]
18. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance. Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779 [TBL] [Abstract][Full Text] [Related]
19. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma. Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103 [TBL] [Abstract][Full Text] [Related]
20. Double germline mutations in the RET Proto-oncogene in MEN 2A and MEN 2B kindreds. Dvorakova S; Vaclavikova E; Ryska A; Cap J; Vlcek P; Duskova J; Kodetova D; Holub V; Novak Z; Bendlova B Exp Clin Endocrinol Diabetes; 2006 Apr; 114(4):192-6. PubMed ID: 16705552 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]